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Background: Malaria remains a major public health problem, and its control has been hampered by drug
resistance. For a number of drugs, Plasmodium falciparum single nucleotide polymorphisms (SNPs) are associated
with altered drug sensitivity and can be used as markers of drug resistance. Several techniques have been studied
to assess resistance markers. The most widely used methodology is restriction fragment length polymorphism
(RFLP) analysis. The ligase detection reaction fluorescent microsphere (LDR-FM) assay was recently shown to
provide high throughput assessment of P. falciparum SNPs associated with drug resistance. The aim of this study
was to validate the reliability and accuracy of the LDR-FM assay in a field setting.
Methods: For 223 samples from a clinical trial in Tororo, Uganda in which P. falciparum was identified by blood
smear, DNA was extracted from dried blood spots, genes of interest were amplified by PCR, amplicons were
analysed by both RFLP and LDR-FM assays, and results were compared.
Results: SNP prevalence (wild type/mixed/mutant) with RFLP analysis was 8/5/87% for pfcrt K76T, 34/37/29% for
pfmdr1 N86Y, 64/17/19% for pfmdr1 Y184F, and 42/21/37% for pfmdr1 D1246Y. These prevalences with the LDR-FM
assay were 7/5/88%, 31/24/45%, 62/20/18%, and 48/19/33% for the four SNPs, respectively. Combining mixed and
mutant outcomes for analysis, agreement between the assays was 97% (K = 0.77) for pfcrt K76T, 79% (K = 0.55) for
pfmdr1 N86Y, 83% (K = 0.65) for pfmdr1 Y184F, and 91% (K = 0.82) for pfmdr1 D1246Y, with most disagreements due
to discrepant readings of mixed genotypes.
Conclusion: The LDR-FM assay provides a high throughput, relatively inexpensive and accurate assay for the surveillance
of P. falciparum SNPs associated with drug resistance in resource-limited countries.
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Malaria, especially that caused by Plasmodium falcip-
arum, remains one of the most important infectious dis-
eases in the world. The treatment and control of malaria
has been greatly hampered by parasite resistance to avail-
able drugs. With widespread resistance to older drugs,
artemisinin-based combination therapy (ACT) is now* Correspondence: prosenthal@medsfgh.ucsf.edu
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article, unless otherwise stated.the standard of care for the treatment of falciparum
malaria. In Uganda, artemether-lumefantrine (AL) was
introduced as first-line treatment for uncomplicated
malaria in 2006 [1].
Mechanisms of resistance to anti-malarial drugs are in-
completely understood. For chloroquine and amodiaquine,
the K76T mutation in the pfcrt gene, which encodes a pu-
tative drug transporter, is the principal mediator of resist-
ance [2]. Polymorphisms in another gene, pfmdr1, which
encodes a protein homologous to transporters that medi-
ate drug resistance in other organisms, modulate levels ofentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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N86Y, Y184F and D1246Y polymorphisms are common,
and the 86Y and 1246Y mutations are associated with de-
creased sensitivity to chloroquine and amodiaquine [4-6].
Interestingly, wild type sequences at these same alleles lead
to decreased sensitivity to artemisinins and the ACT part-
ner drugs lumefantrine and mefloquine [5,7,8]. Given the
limited arsenal of effective ACT and early signs of artemi-
sinin resistance in Southeast Asia [9,10], there is a need for
efficient surveillance of Ugandan parasites for genetic
polymorphisms that may mediate resistance to the most
important anti-malarial drugs.
Several techniques have been developed to detect sin-
gle nucleotide polymorphisms (SNPs) associated with P.
falciparum drug resistance. The most widely used is re-
striction fragment length polymorphism (RFLP) analysis
[11], which is reliable, but fairly expensive and labour in-
tensive. Other relatively low throughput methodologies
include direct DNA sequencing, mutation-specific PCR
[12], dot-blot probe hybridization [13], molecular bea-
cons [14], and single-nucleotide primer extension [15].
Other techniques that have provided improved through-
put include polymorphism-specific microarrays [16], melt-
ing curve analysis [17,18] and quantitative PCR [19-21].
Each of these methodologies has challenges, especially in
resource-limited settings, including cost and availability of
required instruments.
The ligase detection reaction fluorescent microsphere
(LDR-FM) assay allows multiplex assessment of multiple
P. falciparum SNPs [22]. It was recently shown that this
assay is accurate and also less expensive and less labour
intensive compared to RFLP analysis [23]. This new study
compared the LDR-FM assay with RFLP analysis for the
detection of key resistance-mediating P. falciparum SNPs
in samples from a Ugandan clinical trial, with assays
performed in parallel at a Ugandan laboratory.
Methods
Samples for analysis
Control parasite DNA was obtained from the Malaria
Research and Reference Reagent Resource Center. Field
samples were from a longitudinal anti-malarial drug effi-
cacy trial in Tororo, Uganda, the details of which haveTable 1 LDR-FM readings for four SNPs in Plasmodium falcipa
Strain pfmdr 1
86 N 86Y 184Y 184 F
3D7 4,325 119 3,316 251
7G8 3,680 187 197 4,087
DD2 214 1,689 3,810 256
V1/S 126 4,018 3,679 284
Values shown are uncorrected mean fluorescence readings for three to five assays,
Readings representing the known sequences at each allele are in bold type.been published [24]. Briefly, 351 children aged four to
12 months were enrolled and randomized to receive ei-
ther AL or dihydroartemisinin-piperaquine (DP) for each
episode of uncomplicated malaria between 2007 and
2012.
All first episodes of falciparum malaria and all recur-
rent malaria episodes presenting 84 or more days after
prior treatment were studied. Parasite densities were es-
timated by counting the number of asexual parasites per
200 white blood cells and calculating parasites per μL,
assuming a white blood cell count of 8,000 cells/μL. The
study was approved by the Uganda National Council of
Science and Technology and the Institutional Review
Boards of Makerere University College of Health Sciences
and the University of California, San Francisco, USA.
RFLP analysis
DNA was extracted from filter paper with Chelex resin
[25] and alleles were identified by nested PCR (see
Additional file 1 for primers) followed by RFLP ana-
lysis, as previously described [26,27]. Briefly, regions of
interest were amplified, PCR products were treated
with polymorphism-specific restriction endonucleases
(ApoI for pfcrt K76T, AflIII for pfmdr1 N86Y, DraI for
pfmdr1 Y184F, and BglII for pfmdr1 D1246Y), and the
sizes of products were characterized by agarose gel
electrophoresis to distinguish wild type, mutant and
mixed alleles based on comparison with control refer-
ence strain DNA.
LDR-FM analysis
The extracted DNA was amplified by PCR (see Additional
file 2 for primers), as previously described [23]. The ampli-
cons were subjected to multiplex ligase detection re-
actions (see Additional file 3 for primers) in which
bead-specific oligonucleotides and biotin were added,
ligation products were hybridized to magnetic beads, and
polymorphism prevalences were assessed fluorometrically
in a multiplex format using a Magpix instrument (Lumi-
nex). Genotypes were determined based on comparisons
with controls, with a minimum threshold of 400 MFI for
each reaction and correction factors for each SNP, as pre-
viously described [23].rum reference strains
pfcrt
1246D 1246Y CVMNK CVIET SVMNT
3,720 191 1,330 237 281
123 1,452 458 741 3,133
4,773 153 210 2,660 214
3,599 193 309 2,647 315
each run in triplicate. For pfcrt, the haplotype represents amino acids 72–76.
Table 2 Baseline characteristics of the samples utilized in
this study
Characteristic Treatment arm
AL (n = 101) DP (n = 129)




18,534 (8160–74,277) 14,164 (4720–60,800)








3.7 years (1–5) 3.6 years (1–5)
AL artemether-lumefantrine; DP dihydroartemisinin-piperaquine; IQR inter-
quartile range; SD standard deviation.
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Correlation of results between assays was assessed using
kappa statistics.
Results
Analysis of plasmodium falciparum reference strains
The goal of this study was to validate the LDR-FM assay,
using samples from a recent clinical trial, with assays per-
formed at a molecular laboratory in Kampala, Uganda.
The LDR-FM assay was first evaluated with DNA from la-
boratory adapted P. falciparum strains 3D7, 7G8, DD2
and V1/S. Three SNPs in pfmdr1 that are common in
Uganda and a five-amino acid haplotype in pfcrt that dis-
tinguishes chloroquine-sensitive and -resistant parasites
with different geographic backgrounds were assessed [28].
Sequence determinations at all studied polymorphisms





86 N 86Y 184Y 184 F
1 12,560 3,386 106 3,600 209
2 74,080 1,849 1,885 2,083 2,284
3 35,120 812 2,937 177 4,031
4 8,960 3,761 188 2,879 3,361
5 24,560 4,081 125 4,068 322
6 1,440 143 3,777 4,024 292
7 25,520 1,502 3,754 3,928 1,788
8 36,064 2,829 2,846 311 5,227
9 18,320 2,677 132 3,154 555
10 14,840 4,121 100 3,686 267
Values shown are uncorrected mean fluorescence readings. Readings representing
are in bold type.unidentified SNPs five to ten-fold lower than the readings
for correct identifications (Table 1).
Analysis of clinical samples
A total of 230 smear-positive clinical samples were ana-
lysed by both RFLP and LDR-FM assays. The character-
istics describing these samples are shown in Table 2.
Representative uncorrected fluorescence data for ten
samples showed generally good discrimination of wild
type, mixed and mutant genotypes (Table 3). Results
were available from 223 samples for both assays and
these were used for comparisons. Assays were unsuc-
cessful for six RFLP and zero LDR-FM assays for pfcrt,
seven RFLP and seven LDR-FM assays at pfmdr1 86,
seven RFLP and seven LDR-FM assays at pfmdr1 184,
and three RFLP and one LDR-FM assays at pfmdr1
1246. SNP prevalences measured by RFLP analysis and
with the LDR-FM assay were similar at all studied alleles
(Table 4). Agreement between the assays was good, al-
though results varied between the studied alleles (Figure 1).
Most discrepancies were due to a mixed reading with one
assay, compared to a pure mutant or wild type reading
with the other assay. Combining mixed and mutant out-
comes for analysis, agreement between the assays was 97%
(K = 0.77) for pfcrt K76T, 79% (K = 0.55) for pfmdr1 N86Y,
83% (K = 0.65) for pfmdr1 Y184F, and 91% (K = 0.82) for
pfmdr1 D1246Y.
Discussion
The aim of this study was to validate the LDR-FM assay
for the detection of SNPs associated with anti-malarial
drug resistance in a Ugandan laboratory. A total of 230
smear-positive clinical samples were analysed for four
SNPs associated with anti-malarial drug resistance using
RFLP and LDR-FM assays, and results were compared.s
pfcrt
1246D 1246Y CVMNK CVIET SVMNT
2,018 101 1,235 231 174
3,286 309 811 1,678 195
4,140 365 232 2,115 195
4,536 164 207 2,311 214
3,386 93 162 2,438 163
115 2,065 222 2,430 164
2,496 1,881 304 2,440 163
3,148 937 1,119 1,610 211
4,254 143 1,097 1,262 243
196 1,715 1,385 317 231
the sequence call at each allele after correction by subtraction of background
Table 4 Genotype results as analysed by RFLP and LDR-FM assays
Genotype pfcrt K76T pfmdr1 N86Y pfmdr1 Y184F pfmdr1 D1246Y
RFLP LDR-FM RFLP LDR-FM RFLP LDR-FM RFLP LDR-FM
Wild type 17 (8%) 16 (7%) 76 (34%) 69 (31%) 143 (64%) 139 (62%) 94 (42%) 107 (48%)
Mixed 12 (5%) 11 (5%) 83 (37%) 53 (24%) 38 (17%) 45 (20%) 47 (21%) 42 (19%)
Mutant 194 (87%) 196 (88%) 64 (29%) 101 (45%) 42 (19%) 39 (18%) 82 (37%) 74 (33%)
The numbers of samples with each genotype and percentages of total assignments are shown.
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for errors in misclassification, in particular due to chal-
lenges in distinguishing pure and mixed genotypes at each
allele of interest. As seen in a prior study, SNP prevalences
measured by RFLP and LDR-FM analyses were similar at
the studied alleles, with most discrepancies between assays
due to different calls for mixed genotypes, and with DNA
sequencing showing that for 8 of 9 discrepant readings the
LDR-FM result was correct [23].
Several techniques have been assessed to detect SNPs
associated with P. falciparum anti-malarial drug resist-
ance, each with potential advantages and disadvantages
in a resource-limited setting. Of particular importance is
availability of equipment necessary for high throughput
methods. The LDR-FM assay requires an expensive de-
vice, but this unit can provide a range of assays, includ-
ing measurements of serum cytokine levels and antibody
reactivity, suggesting that it will be of value for many
field-based laboratories. Reagent costs for the LDR-FM
assay are also significant, but this is the case with all mo-
lecular assays, and recent estimates suggested that the
assay provides results at about half the reagent costs of
RFLP assessments [23]. Further, throughput was esti-
mated to be five to ten-fold better with the LDR-FM
assay compared to RFLP analysis, offering large potential
savings in personnel costs.Figure 1 Agreement between RFLP and LDR-FM assays. Results
are shown for samples with readings from both assays at the
indicated alleles.Conclusions
The LDR-FM assay, when performed in a developing-
world laboratory, provided accurate assessment of SNPs
associated with anti-malarial drug resistance. This method
offers relatively high throughput and low cost, hence it
will be used for large-scale surveillance of P. falciparum
polymorphisms of interest in ongoing studies in Uganda
[29]. For other field-based laboratories with access to
Magpix instrumentation, this system may offer the most
practical means of large-scale surveillance of P. falciparum
genetic polymorphisms.
Additional files
Additional file 1: PCR primers for RFLP analyses.
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Additional file 3: LDR primers for LDR-FM analyses.
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